Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors
Rosewell Shaw et al. show that a previously developed immunotherapy strategy, coupling oncolytic adenoviral immunotherapy with clinically tested HER2-specific CAR T-cells, is effective against pancreatic ductal adenocarcinoma (PDAC). This combination therapy produces a curative response in both PDAC...
Main Authors: | Amanda Rosewell Shaw, Caroline E. Porter, Tiffany Yip, Way-Champ Mah, Mary K. McKenna, Matthew Dysthe, Youngrock Jung, Robin Parihar, Malcolm K. Brenner, Masataka Suzuki |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2021-03-01
|
Series: | Communications Biology |
Online Access: | https://doi.org/10.1038/s42003-021-01914-8 |
Similar Items
-
Modeling the Efficacy of Oncolytic Adenoviruses In Vitro and In Vivo: Current and Future Perspectives
by: Mary K. McKenna, et al.
Published: (2020-03-01) -
Creating an arsenal of Adeno-associated virus (AAV) gene delivery stealth vehicles.
by: J Kennon Smith, et al.
Published: (2018-05-01) -
Adeno-Associated Virus VP1u Exhibits Protease Activity
by: Justin J. Kurian, et al.
Published: (2019-04-01) -
Adeno-associated virus capsid assembly is divergent and stochastic
by: Tobias P. Wörner, et al.
Published: (2021-03-01) -
Prospects for combined use of oncolytic viruses and CAR T-cells
by: Adam Ajina, et al.
Published: (2017-11-01)